Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 19/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3901865 | 1.00 | HRH3 (1.00) | HRH3 | |
| SCHEMBL3897106 | 1.00 | HRH3 (1.00) | HRH3 | |
| SCHEMBL3900704 | 0.99 | HRH3 (0.97) | HRH3 | |
| SCHEMBL3905920 | 0.94 | HRH3 (1.00) | HRH3 | |
| SCHEMBL3902790 | 0.92 | HRH3 (1.00) | HRH3 | |
| SCHEMBL3900332 | 0.92 | HRH3 (0.85) | HRH3 | |
| SCHEMBL3902855 | 0.91 | HRH3 (0.98) | HRH3 | |
| Hydrochloric Acid SCHEMBL3896501 | 0.91 | HRH3 (0.98) | HRH3 | |
| SCHEMBL3896005 | 0.90 | HRH3 (0.81) | HRH3 | |
| SCHEMBL3900340 | 0.88 | HRH3 (0.77) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1451167-B1 | PHENYLALKYNES | ORTHO MCNEIL PHARM INC (US) | 2006-03-08 | — | — | EP | claimed |
| US-20030144323-A1 | For treatment of disorders and conditions mediated by the histamine receptor; allergies, sleep disorders, dementia | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-07-31 | — | — | US | claimed |
| US-7482364-B2 | Phenylalkynes | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2009-01-27 | — | — | US | disclosed |
| US-7482364-B2 | Phenylalkynes | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2009-01-27 | — | — | US | disclosed |
| US-7446104-B2 | Phenylalkynes | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2008-11-04 | — | — | US | disclosed |
| US-7446104-B2 | Phenylalkynes | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2008-11-04 | — | — | US | disclosed |
| US-20080103135-A1 | PHENYLALKYNES | APODACA RICHARD | 2008-05-01 | — | — | US | disclosed |
| US-20080103135-A1 | PHENYLALKYNES | APODACA RICHARD | 2008-05-01 | — | — | US | disclosed |
| US-20080096876-A1 | PHENYLALKYNES | APODACA RICHARD | 2008-04-24 | — | — | US | disclosed |
| US-7288540-B2 | Phenylalkynes | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2007-10-30 | — | — | US | disclosed |
| US-7288540-B2 | Phenylalkynes | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2007-10-30 | — | — | US | disclosed |
| US-20060258859-A1 | Phenylalkynes | APODACA RICHARD | 2006-11-16 | — | — | US | disclosed |
| EP-1451167-B1 | PHENYLALKYNES | ORTHO MCNEIL PHARM INC (US) | 2006-03-08 | — | — | EP | disclosed |
| EP-1567494-A1 | METHODS FOR PREPARING PHENYLALKYNE DERIVATIVES | Ortho-McNeil Pharmaceutical, Inc. (US) | 2005-08-31 | — | — | EP | disclosed |
| US-6884803-B2 | Phenylalkynes | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2005-04-26 | — | — | US | disclosed |
| EP-1451167-A1 | PHENYLALKYNES | Ortho-McNeil Pharmaceutical, Inc. (US) | 2004-09-01 | — | — | EP | disclosed |
| WO-2004050623-A1 | METHODS FOR PREPARING PHENYLALKYNE DERIVATIVES | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2004-06-17 | — | — | WO | disclosed |
| US-20040002604-A1 | Phenylalkynes | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2004-01-01 | — | — | US | disclosed |
| US-20030144323-A1 | For treatment of disorders and conditions mediated by the histamine receptor; allergies, sleep disorders, dementia | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-07-31 | — | — | US | disclosed |
| WO-2003050099-A1 | PHENYLALKYNES | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2003-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103135-A1 | PHENYLALKYNES | HRH2, HRH3, HNMT | HRH3 2/4885 |
| US-20060258859-A1 | Phenylalkynes | HRH2, HRH3, HNMT | HRH3 2/4885 |
| US-20080096876-A1 | PHENYLALKYNES | HRH2, HRH3, HNMT | HRH3 2/4885 |
| US-20030144323-A1 | For treatment of disorders and conditions mediated by the histamine receptor; allergies, sleep disorders, dementia | HRH3, HRH2, HRH4 | HRH3 1/4885 |
| US-20040002604-A1 | Phenylalkynes | HRH2, HRH3, HNMT | HRH3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.